Addressing Disease Activity and Flares for an Individualized Approach to Managing Systemic Lupus Erythematosus (SLE)

A continuing medical education activity sponsored by NAMCP and AAMCN.

Best Practices in the Treatment and Management of Systemic Lupus Erythematosus (SLE): Addressing Disease Activity and Flares for Improved Clinical and Economic Outcomes is a 3-part live webinar series that will provide attendees with the latest information in Systemic Lupus Erythematosus

This is Part 1 of the series focusing on the management of flares

This activity is an archive from the webinar held July 12, 2018

This activity is valid from September 10, 2018 to September 30, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
GlaxoSmithKline

Description:
Systemic lupus erythematosus (SLE), also known simply as lupus, is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary between people and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face. Often there are periods of illness, called flares, and periods of remission during which there are few symptoms. Diagnosis can be difficult and is based on a combination of symptoms and laboratory tests. Systemic lupus erythematosus (SLE) is the most common form of lupus and affects approximately 70 percent of an estimated 5 million people with lupus worldwide. Approximately 170,000-200,000 Americans live with SLE. Fortunately, over the past decade several new agents have become available, or are on the horizon. These options have proven to reduce lupus disease activity, and developments have been made to make administration easier for improving patient adherence and quality of life. With these recent developments, it is imperative to provide medical directors, primary care physicians, rheumatologists, and others on the interprofessional management team with updated guidelines and strategies for optimizing patient adherence and quality of life, with the ultimate goal of improving patient outcomes.

Upon completion of this activity, participants will be able to:

  • Discuss the impact of uncontrolled systemic lupus erythematosus (SLE) activity on organ damage, mortality, and costs to the healthcare system

  • Assess disease activity and severity, considering the diverse immunopathology and variable expression of SLE in different patients

  • Identifying patients who may be nonadherent to current SLE therapies that focus on reducing flares and disease activity

  • Review the safety and efficacy data on current and emerging SLE treatment to control disease activity and prevent or minimize disease flares, drug toxicity, and organ damage in patients with SLE
     

Faculty: Daniel J. Wallace M.D., FACP, MACR
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA

Disclosure:

Dr. Wallace serves on an advisory board for Amgen, Celgene, EMD Serono, Lilly, and Merck. He serves as a consultant for Amgen, Celgene, EMD Serono, Lilly, and Merck. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
GlaxoSmithKline

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue